Noveome Biotherapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2026-08-27.
Noveome Biotherapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on August 27, 2026. The filing reports $6.75M sold. Its industry group is Biotechnology. It names Patrick Welch (Executive Officer, Director), Robert Langer (Director), Ronald Poropatich (Director) (SEC Form D, August 27, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Selling to Noveome Biotherapeutics, Inc.? See who runs it and how to reach them, plus this week's 25 other newly funded companies.
Is this your company?
Sell to companies like Noveome Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-08-27 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Noveome Biotherapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Noveome Biotherapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in Pennsylvania, filed in August 2026, largest first.
Get an email when Noveome Biotherapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Noveome Biotherapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Noveome Biotherapeutics, Inc. →Get the full cited report on Noveome Biotherapeutics, Inc.
What the filing shows about Noveome Biotherapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Noveome Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Noveome Biotherapeutics, Inc.'s address as 620 Alpha Drive, Suite 2, Pittsburgh, PA 15238.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Noveome Biotherapeutics, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Noveome Biotherapeutics, Inc. See pricing
Noveome Biotherapeutics, Inc. is a registered filer with the SEC (CIK 1478304) and has filed since 2023-08-17. 2 filings are on record, the latest on 2026-08-27.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Noveome Biotherapeutics, Inc.'s Form D of 2026-08-27 names Patrick Welch, Robert Langer, Ronald Poropatich and 6 more as its officers, directors or promoters.
Its new offerings report $27.44M sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $6.75M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Estimated amount represents aggregate salary payments to executive officers.
Checked away from the filing. What is below does not come from the record on sec.gov.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Patrick Welch is named as Executive Officer and Director on the Form D that Noveome Biotherapeutics, Inc. filed with the SEC on 27 August 2026, one of 9 people that filing names.
Robert Langer is named as Director on the Form D that Noveome Biotherapeutics, Inc. filed with the SEC on 27 August 2026, one of 9 people that filing names.
Ronald Poropatich is named as Director on the Form D that Noveome Biotherapeutics, Inc. filed with the SEC on 27 August 2026, one of 9 people that filing names.
Eric Keller is named as Executive Officer and Director on the Form D that Noveome Biotherapeutics, Inc. filed with the SEC on 27 August 2026, one of 9 people that filing names.
Houman Hemmati is named as Director on the Form D that Noveome Biotherapeutics, Inc. filed with the SEC on 27 August 2026, one of 9 people that filing names.
Craig Nemiroff is named as Director on the Form D that Noveome Biotherapeutics, Inc. filed with the SEC on 27 August 2026, one of 9 people that filing names.
Michael Kaufman is named as Director on the Form D that Noveome Biotherapeutics, Inc. filed with the SEC on 27 August 2026, one of 9 people that filing names.
Karin Potoka is named as Executive Officer on the Form D that Noveome Biotherapeutics, Inc. filed with the SEC on 27 August 2026, one of 9 people that filing names.
Larry Brown is named as Executive Officer on the Form D that Noveome Biotherapeutics, Inc. filed with the SEC on 27 August 2026, one of 9 people that filing names.
9 people named on the filing — 4 holding an executive role and 5 as directors only.
Named as of the 2026-08-27 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Noveome Biotherapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Noveome Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Noveome Biotherapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Noveome Biotherapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Noveome Biotherapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (noveome.com).
Each opens in a new tab, filled in for Noveome Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises, week of 2026-08-24 · Biotech raises in Pittsburgh
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/noveome-biotherapeutics-inc-form-d-26000001